- The FDA's Division of Metabolism & Endocrinology Products has told Amarin (AMRN) that it doesn't plan to reinstate a special protocol assessment agreement (SPA) for a trial related to the expanded use of the biopharmaceutical firm's Vascepa drug.
- Amarin intends to appeal the decision to the FDA's director of the Office of Drug Evaluation II.
- The FDA had originally allowed the SPA, but rescinded it in October, saying that it would no longer consider a change in serum triglyceride levels as enough evidence to show efficacy.
- Under the new "ANCHOR" indication, the therapy would be used to treat people who take statins to cut cholesterol and have a high risk of coronary heart disease.
- Shares plummet 26%. (PR)
From other sites
at CNBC.com (Feb 28, 2014)
at CNBC.com (Oct 17, 2013)
at CNBC.com (Aug 22, 2013)
at CNBC.com (Mar 21, 2013)
at CNBC.com (Jan 17, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs